Results 1 to 10 of about 38,166 (233)

Coverage, spatial distribution and determinants of childhood inactivated poliovirus vaccine immunization in Ethiopia. [PDF]

PLoS ONE
IntroductionPolio eradication is a current and common strategy throughout the globe. The study of the newly introduced inactivated poliovirus vaccine provides a grasp on the current status of immunization and identifies any disparities in the ...
Tadesse Tarik Tamir, Belayneh Shetie Workneh, Enyew Getaneh Mekonen, Alebachew Ferede Zegeye   +3 more
doaj   +3 more sources

Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance. [PDF]

Pathogens
Inactivated poliovirus vaccine (IPV), available since 1955, became the first vaccine to be used to protect against poliomyelitis. While the immunogenicity of IPV to prevent paralytic poliomyelitis continues to be irrefutable, its requirement for strong ...
Sutter RW, Eisenhawer M, Molodecky NA, Verma H, Okayasu H.   +4 more
europepmc   +4 more sources

Immunogenicity of Fractional Dose Inactivated Poliovirus Vaccine in India. [PDF]

J Pediatric Infect Dis Soc, 2022
Introduction Following the withdrawal of Sabin type 2 from trivalent oral poliovirus vaccine (tOPV) in 2016, the introduction of ≥1 dose of inactivated poliovirus vaccine (IPV) in routine immunization was recommended, either as 1 full dose (0.5mL ...
Ahmad M, Verma H, Deshpande J, Kunwar A, Bavdekar A, Mahantashetti NS, Krishnamurthy B, Jain M, Mathew MA, Pawar SD, Sharma DK, Sethi R, Visalakshi J, Mohanty L, Bahl S, Haldar P, Sutter RW.   +16 more
europepmc   +4 more sources

Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age. [PDF]

Hum Vaccin Immunother, 2022
An inactivated poliovirus vaccine candidate using Sabin strains (sIPV) grown on the PER.C6® cell line was assessed in infants after demonstrated immunogenicity and safety in adults. The study recruited 300 infants who were randomized (1:1:1:1) to receive
Ong-Lim AL, Shukarev G, Trinidad-Aseron M, Caparas-Yu D, Greijer A, Duchene M, Scheper G, van Paassen V, Le Gars M, Cahill CP, Schuitemaker H, Douoguih M, Jacquet JM.   +12 more
europepmc   +4 more sources

Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey. [PDF]

Lancet Reg Health Am, 2022
Trueba G, Jeyaseelan V, Lopez L, Mainou BA, Zhang Y, Whittembury A, Valarezo AJO, Baquero G, de Aguinaga RR, Salinas LJZ, Mancheno MGS, Chacho DEM, Quentin E, Chevez AE, Rey-Benito G, Mach O.   +15 more
europepmc   +3 more sources

Enhanced Inactivated Poliovirus Vaccine [PDF]

Canadian Journal of Infectious Diseases, 1994
Ronald Gold
doaj   +5 more sources

Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine [PDF]

mBio, 2018
As oral poliovirus vaccine (OPV) causes vaccine-associated paralytic poliomyelitis, the polio endgame strategy introduced by the Global Polio Eradication Initiative calls for a phased withdrawal of OPV and an introduction of inactivated poliovirus ...
Woo-Jin Shin, Daiki Hara, Francisca Gbormittah, Hana Chang, Byeong S. Chang, Jae U. Jung   +5 more
doaj   +3 more sources

Inactivated Poliovirus Vaccine Closing the Type 2 Immunity Gap in Vietnam. [PDF]

J Pediatric Infect Dis Soc, 2022
This was a cross-sectional community-based serological survey of polio antibodies assessing the immunogenicity of inactivated poliovirus vaccine (IPV) focusing on poliovirus serotype 2. IPV was administered to 5-month-old children.
Huyen DTT, Anh DD, Trung NT, Hong DT, Thanh TT, Truong LN, Jeyaseelan V, Lopez Cavestany R, Hendley WS, Mainou BA, Mach O.   +10 more
europepmc   +2 more sources

One Full or Two Fractional Doses of Inactivated Poliovirus Vaccine for Catch-up Vaccination in Older Infants: A Randomized Clinical Trial in Bangladesh. [PDF]

J Infect Dis, 2022
Background The polio eradication endgame called for the removal of trivalent oral poliovirus vaccine (OPV) and introduction of bivalent (types 1 and 3) OPV and inactivated poliovirus vaccine (IPV).
Aziz AB, Verma H, Jeyaseelan V, Yunus M, Nowrin S, Moore DD, Mainou BA, Mach O, Sutter RW, Zaman K.   +9 more
europepmc   +2 more sources

Immunogenicity and safety of concomitant administration of the chinese inactivated poliovirus vaccine with the diphtheria-tetanus-acellular pertussis (DTaP) vaccine in children: A multicenter, randomized, non-inferiority, controlled trial. [PDF]

Front Immunol, 2022
Key point Considering that vaccination with the sIPV and DTaP overlap at the ages of 3 and 4 months in China, to reduce the burden of treatment on parents and increase vaccination coverage rates, we designed a postmarket clinical study of co ...
Sun X, Xu Y, Tang F, Xiao Y, Wang Z, Wang B, Zhu X, Yang X, Chen H.   +8 more
europepmc   +2 more sources